Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Terns Pharmaceuticals logo — Taking the Journey Towards Comprehensive Treatment of Seriou...

Terns Pharmaceuticals

Taking the Journey Towards Comprehensive Treatment of Serious Disease

Founded 2017 United States Foster City, United States 63 employees Post-IPO Equity Total: $348.30M Biotechnology, Health Care +2

General Information

Company Name Terns Pharmaceuticals
Founded Year 2017
Location United States Foster City, United States
Founders / Decision Makers
Team member Team member Team member
Employees 63
Industries Biotechnology, Health Care, Medical Devices +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Terns Pharmaceuticals. To contact Terns Pharmaceuticals, visit ternspharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Terns Pharmaceuticals compare?

A PDF of Terns Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Terns Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Terns Pharmaceuticals

Terns Pharmaceuticals is a United States based biopharmaceutical company established in 2016. The company's primary focus is on developing a diverse portfolio of small-molecule product candidates targeting oncology and obesity. Currently, Terns Pharmaceuticals has three clinical-stage development programs, including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and preclinical GIPR modulator programs. Their recent Post-IPO Equity investment amounted to $86.30M on 20 December 2022. Terns Pharmaceuticals' commitment to the comprehensive treatment of serious diseases and its innovative pipeline make it an intriguing prospect for venture capitalists seeking to invest in the biotechnology, health care, and pharmaceutical sectors. For more detailed information, interested parties can visit www.ternspharma.com.

Business keywords: biopharmaceutical, clinical-stage, oncology, obesity, small-molecule product candidates, allosteric BCR-ABL inhibitor, GLP-1 receptor agonist, THR-β agonist, GIPR modulator programs

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $86.30M -
20 Dec 2022
Post IPO Equity $65.00M 2
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners, Fairmount Funds Management
12 Aug 2022
Series C $87.00M 7
Lilly Asia Ventures OrbiMed Vivo Capital
Lilly Asia Ventures, OrbiMed +5
05 Jan 2021
Series B $80.00M 1
Lilly Asia Ventures
Lilly Asia Ventures
30 Oct 2018
Series A $30.00M -
04 Apr 2018

Latest News

View All
Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges — Cnbc
Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges
Cnbc Aug 04, 2026
U.S.-Iran negotiations, Meta trial verdict, OpenAI shuts Sora and more in Morning Squawk — Cnbc
U.S.-Iran negotiations, Meta trial verdict, OpenAI shuts Sora and more in Morning Squawk
Cnbc Mar 25, 2026

Terns Pharmaceuticals Alternatives & Competitors

View All Alternatives
Terns Pharmaceuticals vs
Cascadian Therapeutics, Inc.
Cascadian Therapeutics, Inc. United States

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developin...

Post-IPO Equity
10 employees
Biotechnology, Health Care
Compare Terns Pharmaceuticals vs Cascadian Therapeutics, Inc.
Terns Pharmaceuticals vs
Domain Therapeutics
Domain Therapeutics France

#biopharma #biotech #drugdiscovery #GPCR #Immunooncology #immunosuppression

Grant
88 employees
Biotechnology, Health Care
Compare Terns Pharmaceuticals vs Domain Therapeutics
Terns Pharmaceuticals vs
Poolbeg Pharma plc
Poolbeg Pharma plc United Kingdom

Focused on the development & commercialisation of innovative medicines. Ticker: POLB

Grant
15 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Terns Pharmaceuticals

Taking the Journey Towards Comprehensive Treatment of Serious Disease
Terns Pharmaceuticals was founded in 2017.
Terns Pharmaceuticals is headquartered in Foster City, United States.
Terns Pharmaceuticals operates in Biotechnology, Health Care, Medical Devices and Pharmaceutical. Its work centres on biopharmaceutical, clinical-stage, oncology and obesity.
Terns Pharmaceuticals has approximately 63 employees.
Terns Pharmaceuticals has completed 5 funding rounds, raising a total of $348.30M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Terns Pharmaceuticals include Cascadian Therapeutics, Inc., Domain Therapeutics, Poolbeg Pharma plc, ESCAPE Bio, ORIC Pharmaceuticals Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Terns Pharmaceuticals and Cascadian Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Terns Pharmaceuticals, https://bouncewatch.com/company/terns-pharmaceuticals, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes